Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NANP | Q8TBE9 | 3/20 | 0.59 |
| ▸ | SELL | P14151 | 1/20 | 0.49 |
| ▸ | SELP | P16109 | 1/20 | 0.49 |
| ▸ | SIGLEC7 | Q9Y286 | 3/20 | 0.48 |
| ▸ | MAG | P20916 | 2/20 | 0.47 |
| ▸ | CD22 | P20273 | 1/20 | 0.45 |
| ▸ | NEU4 | Q8WWR8 | 2/20 | 0.45 |
| ▸ | NEU3 | Q9UQ49 | 2/20 | 0.45 |
| ▸ | NEU2 | Q9Y3R4 | 2/20 | 0.45 |
| ▸ | NEU1 | Q99519 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8664558 | 0.91 | NANP (0.64) | NANPSELLSELPSIGLEC7MAG | |
| SCHEMBL442944 | 0.91 | NANP (0.61) | NANPSELLSELPSIGLEC7MAG | |
| SCHEMBL3746151 | 0.91 | NANP (0.61) | NANPSELLSELPSIGLEC7MAG | |
| SCHEMBL16416308 | 0.89 | NANP (0.59) | NANPSELLSELPSIGLEC7MAG | |
| SCHEMBL8631204 | 0.89 | NANP (0.49) | NANPSELLSELPSIGLEC7MAG | |
| SCHEMBL3808166 | 0.88 | NANP (0.58) | NANPSELLSELPSIGLEC7MAG | |
| SCHEMBL13125452 | 0.88 | NANP (0.74) | NANPSELLSELPSIGLEC7MAG | |
| SCHEMBL2742889 | 0.88 | NANP (0.74) | NANPSELLSELPSIGLEC7MAG | |
| SCHEMBL7066109 | 0.88 | NANP (0.74) | NANPSELLSELPSIGLEC7MAG | |
| SCHEMBL7263212 | 0.88 | NANP (0.62) | NANPSELLSELPSIGLEC7MAG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240058335-A1 | METHODS FOR TREATMENT OF CANCER USING ABL INHIBITORS AND DRUGS TARGETING THE MEVALONATE PATHWAY | DUKE UNIVERSITY (US) | 2024-02-22 | — | — | US | disclosed |
| US-10106855-B2 | Genetic assay to determine prognosis in Polycythemia Vera patients | THE JOHNS HOPKINS UNIVERSITY (US) | 2018-10-23 | — | — | US | disclosed |
| US-20150292028-A1 | Genetic Assay to Determine Prognosis in Polycythemia Vera Patients | THE JOHNS HOPKINS UNIVERSITY | 2015-10-15 | — | — | US | disclosed |
| US-8993297-B2 | Preparation and uses of gene sequences encoding chimerical glycosyltransferases with optimized glycosylation activity | UNIVERSITE DE PROVENCE (AIX MARSEILLE I) (FR) | 2015-03-31 | — | — | US | disclosed |
| WO-2014074847-A1 | A GENETIC ASSAY TO DETERMINE PROGNOSIS IN POLYCYTHEMIA VERA PATIENTS | THE JOHNS HOPKINS UNIVERSITY (US) | 2014-05-15 | — | — | WO | disclosed |
| US-8580757-B2 | Methods of modulating mesenchymal stem cell differentiation | THERMO FISHER SCIENTIFIC BIOSCIENCES INC. (US) | 2013-11-12 | — | — | US | disclosed |
| US-20110263675-A1 | METHODS OF MODULATING MESENCHYMAL STEM CELL DIFFERENTIATION | DHARMACON, INC. | 2011-10-27 | — | — | US | disclosed |
| EP-2019864-B1 | PREPARATION AND USES OF GENE SEQUENCES ENCODING CHIMERICAL GLYCOSYLTRANSFERASES WITH OPTIMIZED GLYCOSYLATION ACTIVITY | UNIV PROVENCE AIX MARSEILLE 1 (FR) | 2011-07-13 | — | — | EP | disclosed |
| US-7776313-B2 | Methods of diagnosing and treating rheumatoid arthritis and osteoarthritis | UNIVERSITY HEALTH NETWORK (CA) | 2010-08-17 | — | — | US | disclosed |
| US-20100105106-A1 | PREPARATION AND USES OF GENE SEQUENCES ENCODING CHIMERICAL GLYCOSYLTRANSFERASES WITH OPTIMIZED GLYCOSYLATION ACTIVITY | UNIVERSITE DE PROVENCE (AIX MARSEILLE I) (FR) | 2010-04-29 | — | — | US | disclosed |
| US-20090191540-A1 | Markers for Viral Infections and Other Inflammatory Responses | COLORADO STATE UNIVERSITY RESEARCH FOUNDATION | 2009-07-30 | — | — | US | disclosed |
| US-20090136591-A1 | METALLOTHIONEIN AS AN EARLY BIOMARKER FOR DEATH SECONDARY TO SEPTIC SHOCK AND AS A NOVEL THERAPEUTIC TARGET FOR SEPTIC SHOCK | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2009-05-28 | — | — | US | disclosed |
| US-20070292881-A1 | Methods of diagnosing and treating rheumatoid arthritis and osteoarthritis | UNIVERSITY HEALTH NETWORK (CA) | 2007-12-20 | — | — | US | disclosed |
| US-20070203083-A1 | Methods Of Regulating Metabolism And Mitochondrial Function | WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH | 2007-08-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240058335-A1 | METHODS FOR TREATMENT OF CANCER USING ABL INHIBITORS AND DRUGS TARGETING THE MEVALONATE PATHWAY | ABL2, ABL1, VAV1 | NANP 1534/4885SELL 3810/4885SELP 3647/4885 |
| US-20110263675-A1 | METHODS OF MODULATING MESENCHYMAL STEM CELL DIFFERENTIATION | MYADM, MSI2, RBM3 | NANP 3159/4885SELL 4306/4885SELP 3890/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.